After an extended vacay, I'm back. Blimey, Painchek is goddam slow at commercializing.
Sad to say I messed up with the investment in this company, but holding on due to catalysts like FDA could turn things around. In saying that, I would much rather have them be bought out by ResMed, like what happened with Resapp and Pfizer.
$200M market cap if it ever gets there is where I would sell. Management is way too slow in producing results. The revenues are plateauing; funnily enough, Painchek is approaching the total addressable market in Australia ~ $4M p.a. Replicating this internationally requires more resources which they currently don't have.
PCK Price at posting:
3.1¢ Sentiment: Hold Disclosure: Held
